Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, MAD study in healthy male and female adult subjects. The study will include up to 48 subjects (12 subjects per cohort) who will be randomized 9:3 to active drug or placebo. Each cohort will receive AZD4041 or placebo in a MAD study. A sequential cohort MAD design will be employed to assure that higher doses are administered to healthy subjects only after lower doses have demonstrated an acceptable safety profile. The total study duration will be up to 59 days (including Screening) per subject.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05209334
Study type Interventional
Source MedImmune LLC
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Status Recruiting
Phase Phase 1
Start date December 17, 2021
Completion date April 12, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04111939 - HEALing Communities Study N/A
Withdrawn NCT03547882 - Addiction Treatment in Primary Care Expansion
Recruiting NCT04464980 - Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) Phase 2
Completed NCT05233085 - A Safety Study of AZD4041 in Healthy Participants Phase 1